Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease: A Care Team Forum℠

Activity Overview

This activity is designed to engage your critical thinking about patients who may have alpha-1 antityrypsin deficiency (AATD) and to challenge suboptimal approaches to the management of patients with AATD lung disease. You will hear unique insights from 3 clinical experts and a patient living with AATD during this dynamic presentation.

Credit Expired
CE Credit Expired
Expires: September 12, 2020

Target Audience

The target audience for this activity is clinicians who can impact the recognition and management of patients with alpha-1 antityrypsin deficiency (AATD) lung disease.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Demonstrate improved ability to identify alpha-1 antityrypsin deficiency (AATD) in their patients affected by chronic obstructive pulmonary disease (COPD)
  • Identify patients at risk for AATD and implement guideline-recommended testing
  • Discuss the efficacy data and guideline recommendations for augmentation therapy used to treat AATD
  • Develop individualized treatment plans for patients with AATD using all available clinical information about the patient, including information about physiological health status

Activity Faculty

Robert A. Sandhaus, MD, PhD, FCCP (Chair)

Professor, Medicine
Director , Alpha-1 Program
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources